- Home
- NRSN vs CLDI Comparison
NRSN vs CLDI Comparison
Compare NRSN & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRSN
- CLDI
- Stock Information
- Founded
- NRSN 2017
- CLDI 2014
- Country
- NRSN Israel
- CLDI United States
- Employees
- NRSN N/A
- CLDI N/A
- Industry
- NRSN Biotechnology: Pharmaceutical Preparations
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NRSN Health Care
- CLDI Health Care
- Exchange
- NRSN Nasdaq
- CLDI Nasdaq
- Market Cap
- NRSN 17.8M
- CLDI 18.1M
- IPO Year
- NRSN 2021
- CLDI N/A
- Fundamental
- Price
- NRSN $1.09
- CLDI $0.89
- Analyst Decision
- NRSN Hold
- CLDI Strong Buy
- Analyst Count
- NRSN 1
- CLDI 3
- Target Price
- NRSN N/A
- CLDI $16.67
- AVG Volume (30 Days)
- NRSN 374.5K
- CLDI 1.2M
- Earning Date
- NRSN 12-18-2024
- CLDI 03-14-2025
- Dividend Yield
- NRSN N/A
- CLDI N/A
- EPS Growth
- NRSN N/A
- CLDI N/A
- EPS
- NRSN N/A
- CLDI N/A
- Revenue
- NRSN N/A
- CLDI N/A
- Revenue This Year
- NRSN N/A
- CLDI N/A
- Revenue Next Year
- NRSN N/A
- CLDI N/A
- P/E Ratio
- NRSN N/A
- CLDI N/A
- Revenue Growth
- NRSN N/A
- CLDI N/A
- 52 Week Low
- NRSN $0.51
- CLDI $0.73
- 52 Week High
- NRSN $2.33
- CLDI $16.80
- Technical
- Relative Strength Index (RSI)
- NRSN 47.35
- CLDI 32.62
- Support Level
- NRSN $1.01
- CLDI $0.83
- Resistance Level
- NRSN $1.13
- CLDI $0.95
- Average True Range (ATR)
- NRSN 0.09
- CLDI 0.12
- MACD
- NRSN -0.01
- CLDI -0.03
- Stochastic Oscillator
- NRSN 27.27
- CLDI 11.29
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, these diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical stage immuno-oncology company pioneering the development and commercialization of novel, potent and efficient stem cell-based platforms for delivery and potentiation of oncolytic viruses for the treatment of cancer.